Invivyd Inc.
$ 2.22
-0.45%
04 Dec - close price
- Market Cap 519,864,000 USD
- Current Price $ 2.22
- High / Low $ 2.28 / 2.18
- Stock P/E N/A
- Book Value 0.43
- EPS -0.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.68 %
- 52 Week High 3.07
- 52 Week Low 0.36
About
Invivyd Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the discovery and development of advanced antibody-based therapies to combat infectious diseases. The company leverages its proprietary technologies and extensive immunology expertise to address critical unmet medical needs, highlighted by a promising pipeline of innovative therapeutic solutions. By focusing on the development of targeted antibody therapies, Invivyd positions itself at the forefront of biopharmaceutical advancements, aiming to enhance patient outcomes and respond effectively to global health challenges.
Analyst Target Price
$10.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-15 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-14 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.06 | -0.12 | -0.14 | -0.15 | -0.51 | -0.4 | -0.38 | -0.67 | -0.36 | -0.46 | -0.32 | -0.25 |
| Estimated EPS | -0.07 | -0.02 | -0.01 | -0.1 | -0.35 | -0.37 | -0.47 | -0.42 | -0.5 | -0.34 | -0.3 | -0.39 |
| Surprise | 0.01 | -0.1 | -0.13 | -0.05 | -0.16 | -0.03 | 0.09 | -0.25 | 0.14 | -0.12 | -0.02 | 0.14 |
| Surprise Percentage | 14.2857% | -500% | -1300% | -50% | -45.7143% | -8.1081% | 19.1489% | -59.5238% | 28% | -35.2941% | -6.6667% | 35.8974% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IVVD
2025-10-14 10:36:48
Invivyd, Inc. shares have seen a 31% gain in the last month, bringing their annual gain to 89%. Despite this robust price increase, the company's price-to-sales (P/S) ratio of 7.9x is still considered low compared to the Biotech industry, primarily due to concerns about future growth. Analysts forecast 80% annual revenue growth for Invivyd over the next three years, which is substantially lower than the 128% annual growth projected for the broader industry, justifying the suppressed P/S ratio.
2025-09-17 07:01:00
Invivyd, Inc. announced the appointment of Kristie Kuhl as Chief Communications Officer. Kristie Kuhl will lead the company's communications and patient advocacy efforts, bringing expertise in healthcare and pharmaceutical communications from her previous role as Global Managing Director, Health & Wellness at Zeno Group. This appointment is significant as Invivyd aims to advance its mission of providing monoclonal antibodies for viral disease prevention and treatment and build scientific credibility and trust with stakeholders.
2025-07-23 00:00:00
Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company with a US$92m market cap, is reportedly nearing profitability, with analysts forecasting a shift from a US$143m loss to a US$123m profit in 2026. The company is expected to breakeven just over a year from now, requiring an optimistic annual growth rate of 52%. Notably, Invivyd operates debt-free, relying solely on shareholder funding, which reduces investment risk.
2025-07-08 00:00:00
Invivyd, Inc. has formed the SPEAR (Spike Protein Elimination and Recovery) Study Group to investigate pemivibart, a monoclonal antibody, for treating Long COVID and COVID-19 Post-Vaccination Syndrome (PVS). This initiative follows anecdotal reports of patient improvement and aims to assess the drug's safety, biological mechanisms, and exploratory efficacy in patients with persistent SARS-CoV-2 spike protein exposure. Pemivibart has already demonstrated an 84% relative risk reduction in symptomatic COVID-19 in immunocompromised individuals during the CANOPY trial and maintains neutralizing activity against emerging variants.
2024-12-29 12:02:00
Invivyd, Inc., a biotechnology firm, has been warned by Nasdaq about potential delisting due to its stock price falling below the $1.00 minimum bid price for 30 consecutive business days. The company has until June 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Despite the challenge, Invivyd maintains strong gross profit margins and is exploring options to address the deficiency.
2024-10-29 00:00:00
Invivyd's CANOPY Phase 3 clinical trial of pemivibart (Pemgarda) demonstrated a 76% relative risk reduction in symptomatic COVID-19 over 12 months, including a 64% reduction during the off-drug follow-up period. The investigational monoclonal antibody showed consistent safety and offered substantial protection even at low serum concentrations, highlighting its potential for pre-exposure prophylaxis, particularly in immunocompromised individuals. The findings underscore the continuous need for effective preventive measures against evolving COVID-19 variants.
